Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers

Key Points

• TNBC treatments involving nanobodies and aptamers show promising advancements for better targeting.
• Recent findings indicate that using targeted biological agents can improve treatment efficiency significantly.
• Analysis focuses on integrating various biologics, including antibodies and peptides, to enhance therapeutic outcomes.
• These developments highlight the need for novel treatment options, particularly for this aggressive cancer type.